First tests of experimental coronavirus vaccine starts in US

US, WASHINGTON (ORDO NEWS) — On Monday, American experts began testing the first experimental vaccine for the new coronavirus. According to the Associated Press (AP), the first injection was made at the Kaiser Permanente Washington Health Research Institute in Seattle, Washington.

The mRNA-1273 vaccine prototype was developed by the US National Institutes of Health and Moderna, a biotechnology company in Massachusetts. As noted by AP, the participants in the experiment have no chance of becoming infected, since the injections made by him do not contain coronavirus.

This is just the beginning of the whole series of trials needed to demonstrate that the vaccine is safe and effective, the agency said.

Even if further research is successful, the vaccine may be available for widespread use within 12-18 months. In addition to this vaccine prototype, according to AP, Inovio Pharmaceuticals is currently developing its drug. His trials are expected to begin in April in the United States, China, and South Korea.

As CNN reported on Monday, citing data from the US Federal Centers for Disease Control and Prevention, the number of new coronavirus infections in the United States increased to 3,563, and 65 people died.

The outbreak of the disease caused by the new coronavirus in Central China at the end of 2019 spread to more than 130 countries and was recognized as a pandemic by the World Health Organization (WHO) on March 11.

According to the latest data, more than 170 thousand people have become infected in the world, more than 6 thousand have died. According to the operational headquarters, 93 cases of infection have been registered in Russia.

Online:

Our Standards, Terms of Use: Standard Terms And Conditions.

Contact us: [email protected]

The article is written and prepared by our foreign editors from different countries around the world – material edited and published by Ordo News staff in our US newsroom press.

Leave a Reply

Your email address will not be published.